DKK1 and cancer: Sirexatamab (Leap Therapeutics), a humanized IgG4-κ antibody, has progressed to phase 2 clinical studies in multiple solid tumor types, including gastrointestinal tract-associated tumors and some reproductive cancer types, and several other anti-DKK1 antibody drugs have been utilized in both cancer and bone disease studies.